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Role of CD248 as a potential severity
marker in idiopathic pulmonary fibrosis
Domokos Bartis1,2*, Louise E. Crowley1, Vijay K. D’Souza1, Lee Borthwick3, Andrew J. Fisher3,4, Adam P. Croft5,
Judit E. Pongrácz2, Richard Thompson6, Gerald Langman7, Christopher D. Buckley5 and David R. Thickett1
Abstract
Background: CD248 or Endosialin is a transmembrane molecule expressed in stromal cells binding to extracellular
matrix (ECM) components. It has been previously implicated in kidney fibrosis, rheumatoid arthritis as well as in
tumour-stromal interactions. This study investigates the role of CD248 in the pathogenesis of fibrotic diseases in
Idiopathic Pulmonary Fibrosis (IPF).
Methods: CD248 quantitative immunohistochemistry (IHC) was performed on lung samples from 22 IPF patients
and its expression was assayed in cultured pulmonary fibroblasts and epithelial cells. Effects of CD248 silencing was
evaluated on fibroblast proliferation and myofibroblast differentiation.
Results: IHC revealed strong CD248 expression in mesenchymal cells of normal lung structures such as pleura and
adventitia but not in epithelium. Fibrotic areas showed markedly stronger staining than unaffected lung tissue. The
extent of CD248 staining showed a significant negative correlation to lung function parameters FEV1, FVC, TLC, and
TLCO (r2 > 0 · 35, p < 0 · 01). CD248 protein levels were significantly greater in IPF-derived lung fibroblasts vs normal
lung fibroblasts (p < 0 · 01) and CD248 silencing significantly reduced the proliferation of lung fibroblasts, but did
not affected myofibroblast differentiation.
Conclusion: We conclude that CD248 overexpression is possibly involved in the pathogenesis of IPF and it has
potential as a disease severity marker. Given that CD248 ligands are collagen type I, IV and fibronectin, we
hypothesise that CD248 signalling represents a novel matrix-fibroblast interaction that may be a potential
therapeutic target in IPF.
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Background
Idiopathic pulmonary fibrosis (IPF) is the most common
form of interstitial lung diseases (ILD) with a worldwide
incidence ranging between 14–43 per 100 000 individ-
uals and an average incidence of 7.44 per 100 000 in the
UK [1]. A recent clinical data analysis of UK patient co-
horts by Navaratnam et al. showed a yearly 5 % increase
in incidence which was independent of the ageing of the
population [2].
Lung function progressively deteriorates in IPF pa-
tients leading to respiratory failure and finally death with
a median survival around three years from diagnosis [3].
Therapeutic options for IPF are limited to date, with pir-
fenidone and nintedanib being the only medications
which seem to slow down disease progression and they
have only been tested in patients with mild disease [4, 5].
These drugs are both expensive and real life usage sug-
gests that toxicity leading to drug discontinuation is
higher than reported in the licensing trials [6].
The pathophysiology of IPF is complex involving
fibroproliferation, epithelial cell apoptosis, epithelial-
mesenchymal transition (EMT), neo-angiogenesis, and
intra-alveolar coagulopathy [7–9]. In fibrotic tissue, ef-
fector cells are activated fibroblasts or myofibroblasts res-
iding in large numbers in fibroblastic foci, a characteristic
feature of usual interstitial pneumonia. These alpha
smooth muscle actin (α-SMA)-expressing cells secrete
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large amounts of collagen and other extracellular matrix
(ECM) components and are thus considered to be respon-
sible for pathological tissue remodelling [10]. Pro-fibrotic
growth factors including transforming growth factor-beta
1 (TGF-β1) and platelet-derived growth factor (PDGF) are
believed to drive the fibro-proliferative process in IPF and
promote fibroblast-to-myofibroblast differentiation and
collagen deposition [9, 10]. The degree of involvement of
EMT in IPF pathogenesis—particularly the number of fi-
broblasts and myofibroblasts derived from transdifferen-
tiated epithelial cells—is currently debated [7, 11, 12].
CD248 (also termed Endosialin and TEM-1), is a heav-
ily glycosylated transmembrane protein that was identi-
fied initially as a cell surface marker overexpressed in
tumour vasculature [13]. Later it was revealed that in
fact CD248 was expressed by pericytes, and not the
underlying endothelium [14]. CD248 is now regarded as
a mesenchymal marker, expressed on various fibroblast
types, pericytes, mesenchymal stem cells, smooth muscle
cells and osteoblasts [15, 16]. CD248 is also implicated
in the regulation of the proliferation of mesenchymal el-
ements [17, 18].
CD248 was demonstrated to be overexpressed in vari-
ous mesenchymal cells in pathological conditions includ-
ing sarcomas [19], inflammation [20] and fibrosis [21].
In renal fibrosis CD248 expression was found to relate
to the severity of the disease [21]. There is no informa-
tion about CD248 expression in lung disease especially
IPF. We hypothesised that CD248 expression would be a
marker of severity in IPF. We also investigated its role in
fibroproliferation and EMT.
Methods
Patient samples
Lung tissue samples for histology were obtained by diag-
nostic video assisted thoracoscopic (VATS) lung biopsy
and transplant explants. These procedures were per-
formed by surgical teams at Heartlands Hospital and the
Queen Elizabeth Hospital, Birmingham between the
time-frame January 2005 to December 2012. Lung resec-
tions were fixed in formalin, embedded into paraffin and
sectioned according to standard procedures. A total of
22 patients’ samples were included in the study. Demo-
graphic and clinical data of patients were obtained from
electronic and paper records. Patient data is summarized
in Table 1. No patients received disease modifying treat-
ment (pirfenidone or nintedanib) prior to surgery.
Primary human lung fibroblasts were isolated from
explanted lung tissue of patients with IPF, acquired at
the time of lung transplantation (n = 6) and lung tissue
Table 1 Patient demographics and clinical data. We analysed the demographic and clinical data of 22 patients with a histologically
confirmed IPF diagnosis. 11 of the patients underwent VATS and had mild-to-moderate fibrotic changes in the lung. Another 11 IPF
patients underwent lung transplantation because of severe or end-stage fibrosis. There was no significant difference between the
patient groups’ age, smoking status and body mass index (BMI). The lung function parameters Forced Expiratory Volume in 1 s (FEV1),
Forced Vital Capacity (FVC), Total Lung Capacity (TLC) and Transfer factor for carbon monoxide in the lung (TLCO) were significantly
higher in the patient group with mild-to-moderate fibrotic changes compared to those with severe or end-stage fibrosis
(p < 0.01 using Students unequal variance t-test)
Patients with mild-to-moderate fibrosis
(VATS biopsy patients)
Patients with severe or end-stage fibrosis
(Lung transplant patients)
p-value
(Students t-test)
Demographic and clinical data
N 11 11 -
Sex 4 males, 7 females 9 males, 2 females -
Median age (range) 66 (39–76) 58 (44–61) 0.126
Smoking in history (percent) 7 (63 %) 7 (63 %) 0.482
Pack years (mean ± SEM) 28.37 ± 11.97 21.93 ± 6.61 0.784
BMI (mean ± SEM) 28.87 ± 1.37 27.67 ± 1.87 0.636
Lung function
FEV1 (mean ± SEM) 2.51 ± 0.19 1.59 ± 0.20 0.0009
FVC (mean ± SEM) 3.21 ± 0.32 1.92 ± 0.23 0.0006
TLC (mean ± SEM) 4.77 ± 0.54 3.04 ± 0.34 0.0014
TLCO (mean ± SEM) 3.69 ± 0.36 2.09 ± 0.30 0.0099
Medication (given only after biopsy)
Prednisolone 6 (54.5 %) 8 (72.7 %) -
Azathioprine 3 (27.2 %) 4 (36.3 %) -
N-acetylcysteine 4 (36.3 %) 2 (18.1 %) -
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from healthy donors rejected for transplantation as con-
trols (n = 6) at the Institute of Transplantation, Newcastle
Upon Tyne Hospitals NHS Trust. All procedures in this
study were performed in accordance with approval from
the local research ethics committees at the University of
Birmingham and Newcastle University, respectively. All
patients gave written informed consent for the use of their
tissue and clinical data for research purposes. Ethics com-
mittee approval number is 07/MRE08/42.
Immunohistochemistry and digital image analysis
Lung tissue samples for immunohistochemistry (IHC)
were obtained by VATS from patients with mild-to-
moderate fibrosis (n = 11) or were taken from lungs of
patients with end-stage fibrosis undergoing lung trans-
plantation (n = 11). Sections were processed for CD248
immunohistochemical staining using standard methods
for diaminobenzidine (DAB) chromogen and haema-
toxylin for nuclear staining. The B1/35.1 anti-human
CD248 antibody [14] was used for IHC in an automated
IHC staining system (Roche Benchmark Ultra). The area
staining positive for CD248 was compared between the
two patient groups using the ImageJ software for digital
image analysis as follows: we took 3–7 high resolution
digital images per slide at random locations. Patient
identification were blinded during the whole analysis.
CD248 signal and haematoxylin signal on the images
were digitally separated using the Colour Deconvolution
plugin for ImageJ [22]. Threshold value was set manually
at the same levels in both of the channels on all of the
images. The area above the threshold was summarised
for each image, representing the area stained positive for
CD248 or haematoxylin on each image. CD248 positive
area was compared to the haematoxylin staining area
representing relative CD248 expression in the lung sam-
ples of IPF patients. A graphical explanation of this
method is shown on Fig. 2a. The relative CD248 staining
area were compared between transplant and VATS
biopsy patients. We used both Student’s t-test and
Mann–Whitney U-test for statistical analysis of the data
derived from images, where p < 0.05 denoted statistical
significance.
Cell culturing and treatments
Normal human lung fibroblasts (NHLF) were purchased
from Promocell (Heidelberg, Germany). At least 3
batches from different patents were used for every ex-
periment. NHLFs were initially cultured and expanded
in Fibroblast Growth Medium (Promocell) according to
the supplier’s instructions. A549 human lung adenocar-
cinoma cell line was maintained in DMEM supple-
mented with 2 mM L-glutamine, HEPES, non-essential
amino acids, 100 U/ml penicillin and 100 mg/ml
streptomycin and 10 % FCS.
Additional primary fibroblasts were isolated at
Newcastle University from the lungs of patients with
advanced IPF and the lung tissue from healthy donors
rejected for transplantation as controls at the Insti-
tute of Transplantation, Newcastle Upon Tyne Hospi-
tals NHS Trust. The isolation method based on a cell
outgrowth technique. Briefly, lung tissue pieces
(<1 mm3) were cultured in DMEM/F12 (Sigma) sup-
plemented with 10 % FCS, 1 % L-glutamine, 100U/ml
penicillin and 100 μg/ml streptomycin to allow cells
to migrate out of the tissue. After 7 days the tissue is
removed and the cells grown to confluence. Mesen-
chymal phenotype was confirmed by positive expres-
sion of fibronectin, vimentin and α-smooth muscle
actin and little/no expression of E-cadherin, ZO-1
and CD45. Fibroblasts were used at the third passage
in all experiments.
Human Primary Lung epithelial cells were isolated
from tissue samples from lobectomy patients with nor-
mal lung function. Cells were isolated and cultured as
described elsewhere [23]. TGF-β1 was obtained from
R&D Systems (Abingdon, UK). Final concentration of
TGF-β1 was 10 ng/ml.
siRNA transfection
CD248 knock-down (KD) in NHLFs was carried out
using specific siRNA (Life Technologies). We used Lipo-
fectamine 2000 reagent and Opti-MEM (both from Life
Technologies) according to the manufacturer’s instruc-
tions. Cells were cultured after transfection for 48 h. Ef-
ficiency of KD was determined using PCR and flow
cytometry (Additional file 1: Figure S4A and B, respect-
ively). Cell viability was >95 % after 48 h of siRNA trans-
fection as determined by the trypan-blue exclusion test.
Proliferation assay
A commercial ELISA-based bromodeoxyuridine (BrdU)
proliferation assay kit was used from Calbiochem
(Watford, UK) according to the manufacturer’s in-
structions. Briefly, previously serum-starved cells were
seeded into a 96-well tissue culture plate in DMEM +
0.1 % FCS; BrdU and stimulants were added after-
wards. Cells were incubated for 24 h to incorporate
BrdU, then the proliferation was stopped using the
fixative agent supplemented with the kit. The devel-
opment and colorimetric measurements were per-
formed according to the manufacturer’s instructions.
Proliferation experiments were repeated for at least 3
times with cells from 3 different donors.
Flow cytometry
Cultured cells were detached using a non-enzymatic cell
dissociation solution (Sigma Aldrich) to preserve the
trypsin-sensitive CD248 epitope. Labelling was carried
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out using an anti-CD248-FITC monoclonal antibody [24].
Samples were analysed on a CyanADP Analyzer flow cyt-
ometer and Summit v4.3 software. CD248 protein expres-
sion is presented as median fluorescent intensity (MFI).
Real time qPCR
Total RNA was isolated from cultured cells using the
NucleoSpin RNA isolation kit with on-column DNase di-
gestion (Machery-Nagel), cDNA synthesis was performed
using a High Capacity RNA-to-cDNA kit (Applied Biosys-
tems) following manufacturer’s protocols. For real-time
qPCR experiments, master mixes with or without SYBR
Green were used (Roche). The list of primers is available
in the online supplement. (Additional file 1: Table S1)
PCR experiments were performed on a Light Cycler 480
Instrument (Roche). In the plots reverse ΔCt values versus
GAPDH expression are presented; the calculation formula
was reverse ΔCt = Ct(GAPDH) - Ct(Target) [25]. The
mean Ct values were calculated for 3 or more independent
experiments.
Statistics
Data were analysed on using SPSS for Windows 16.0
(SPSS, Inc., Chicago, IL). Data were tested for normality
using Spearman’s chi squared test and analysed by non-
equal variance t test or Mann–Whitney U test. Data are
expressed as mean ± SE unless otherwise indicated. Cor-
relations were calculated using least squares linear re-
gression test.
Results
CD248 immunohistochemistry staining pattern on fibrotic
lung
CD248 expression was compared in lung samples
from patients with IPF who underwent either VATS
biopsy (mild or moderate fibrotic changes, n = 11) or
lung transplantation (severe or end-stage fibrotic
changes, n = 11). CD248 expression was observed spe-
cifically on fibroblast-like stromal cells but not on
epithelium, endothelium, smooth muscle, alveolar
macrophages or inflammatory cells (Fig. 1, Additional
file 1: Figure S1). Areas of fibrosis stained positive for
CD248. There was a range of weak to strong staining
in the fibrotic regions with the more established fi-
brosis showing greater CD248 expression levels. There
was a visible difference between CD248 expression
patterns in lung samples with mild or moderate fibro-
sis and severe fibrosis (Fig. 1a and b, respectively.) Fi-
broblastic foci generally stained less intensive or not
at all for CD248 in comparison to the surrounding fi-
brosis (see Fig. 1c).
In contrast to fibroblasts, epithelial cells in the lung
stained negative for CD248 (Fig. 1d) and some of the
physiological structures in the lung proved to be conse-
quently positive for CD248, like the adventitia of larger
muscular arteries, interlobular septa and pleural regions
(Additional file 1: Figure S1). Staining in these latter
structures was universally greater than that observed in
fibrotic areas. In addition, staining around the bronchioles
Fig. 1 Panel a: Typical CD248 staining patterns in the fibrotic lung in a sample obtained by VATS biopsy from an IPF patient with mild/moderate
fibrotic changes in the lung. Original magnification 40x.: Panel b: Typical CD248 staining in end-stage fibrosis in the lung sample of an IPF patient
undergone lung transplantation. Original magnification 40x. Panel c: Pale CD248 staining (brown) in fibroblastic foci (arrows) compared to
adjacent scarring (stars), (original magnification x200). Panel d: IHC staining of CD248 in IPF patient. The epithelium in dilated air spaces is
negative for CD248 (arrow) while adjacent fibrotic stromal regions (stars) show pale to moderate CD248 staining. (original magnification
x100). Slides were visualized using an Olympus BX51 microscope (Olympus) and photographed with an Olympus C3030 camera (Olympus)
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was seen but areas of inflamed interstitium exhibited very
little CD248 expression. (Additional file 1: Figure S1).
CD248 expression in the lung of IPF patients is significantly
associated with the severity of fibrosis and lung function
Since staining intensity with DAB is not proportional to
expression level [22] we compared the relative area
stained positive for CD248 by comparing DAB staining
(e.g. CD248 positive areas) to the area of nuclear stain-
ing with haematoxylin (Fig. 2a). We found, that the area
stained positively for CD248 was significantly higher in
the transplant explant samples than in patients undergo-
ing VATS biopsy (Fig. 2b) For further statistical informa-
tion on please see Additional file 1: Figure S2).
Importantly in univariate analysis there was a signifi-
cant negative correlation with the relative staining area
of CD248 with lung function. Our data show that FEV1,
FVC, TLCO and TLC are significantly correlated to
CD248 staining in fibrotic lungs (r2 value between 0.35
and 0.5; p < 0.05 using non-parametric ANOVA, detailed
data are presented in Table 2 and graphical presentation
of the data are in Additional file 1: Figure S3.
CD248 expression levels are higher in fibroblasts derived
from IPF patients than those from normal lungs
To confirm that CD248 expression is higher in IPF fi-
broblasts compared to normal fibroblasts, expression
was compared by qPCR and flow cytometry.
Fig. 2 Panel a: Graphical explanation of the digital image analysis using the Colour Deconvolution ImageJ plugin. The digital images taken of the
IPF sections opened in ImageJ and DAB (brown) and Hematoxylin (blue) channels were digitally separated using the plugin. Then both resulting
images were transformed to 8-bit greyscale images and after threshold levels were applied resulting 1 bit images. We compared Hematoxylin-
stained and DAB-stained pixel numbers above the threshold on the 2 images so that we get a relative CD248 staining area. Panel b: Comparison
of the relative areas stained positively for CD248 in IPF patient groups plotted on a dot plot diagram, horizontal lines representing the median
value. On the diagram we plotted relative staining areas on sections obtained from IPF patients with mild-to-moderate fibrosis (n = 11, samples
obtained by VATS biopsy) and lung transplant patients with severe or end-stage fibrotic changes (n = 11). In VATS biopsy patients with mild-to-
moderate fibrotic changes significantly smaller area (median value = 0.45) stained positively for CD248 when compared to those with severe or
end-stage lung fibrosis (median value = 1.19; p < 0.05 using Mann–Whitney U-test)
Table 2 Summary of regression analysis data. The normal
distribution of all datasets were analysed and confirmed using
the Chi square goodness-of-fit method (data not shown). R
squared values were calculated using the least squares linear
regression analysis. The significance of the correlation were
analysed using ANOVA test
Correlation to
CD248 relative
staining area
R squared values
(least squares
linear regression)
Significance
of correlation
(ANOVA)
Demographics/
clinical data
Age 0.097 0.156
Smoking
(pack-years)
0.084 0.226
Lung function
data
TLC 0.432 0.005
FVC 0.358 0.003
FEV1 0.392 0.002
TLCO 0.455 0.008
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There was no significant difference in mRNA expres-
sion of CD248 between normal and IPF derived fibro-
blasts (Fig. 3c). In contrast CD248 protein expression
was significantly increased when measured using flow
cytometry (Fig. 3a and b). Interestingly, CD248 expres-
sion seemed to be sensitive to TGF-β1 treatment in IPF
fibroblasts but not in normal fibroblasts (Fig. 3b) with
TGF-β1 reducing expression.
CD248 regulates fibroblast proliferation but not
myofibroblast transdifferentiation and collagen synthesis
in vitro
In order to establish a functional role for CD248 in
fibroblast function we transfected NHLFs with negative
control or CD248-specific siRNA for 48 h, then assayed
the bromodeoxyuridine (BrdU) uptake of the cells with
ELISA. CD248 expression levels after knockdown were
assessed with qPCR and FACS (Additional file 1: Figure
S4). We found, that CD248 knockdown significantly re-
duced NHLF BrdU uptake (Fig. 4a). We tested, whether
CD248 knockdown had any effect on in vitro myofibro-
blast transdifferentiation by assessing alpha smooth
muscle actin (alpha-SMA) and collagen-1 mRNA and
protein levels. We found, that CD248 knockdown did
not induce myofibroblast differentiation as there were
no significant differences in collagen and alpha-SMA
levels between control and CD248 KD samples.
CD248 expression is not induced by EMT in lung
epithelial cells
CD248 is a mesenchymal marker expressed on fibro-
blasts but not on epithelial cells in the lung. We tested
whether CD248 is expressed by pulmonary epithelial
cells undergoing epithelial-mesenchymal transition in
vitro using both reverse-transcription qPCR and flow cy-
tometry. We found that CD248 mRNA is expressed in
epithelial cells at a very low level and protein expression
is negative with flow cytometry. Addition of TGF-β1 did
not induce CD248 expression but induced changes char-
acteristic for EMT (Fig. 5).
Discussion
In this study we have evaluated CD248 expression in the
lungs of patients with mild early stage IPF and lung
transplant explants. Immunohistochemistry demon-
strated intense staining of established fibrotic areas of
the lung and expression related to the severity of lung
function abnormalities. We confirmed increased expres-
sion of CD248 in IPF derived fibroblasts compared to
normal primary pulmonary fibroblasts.
Formation of fibroblastic foci is a key feature reflecting
sites of active on-going fibrogenesis. Increased numbers
of fibroblastic foci have been associated with disease ac-
tivity and a more rapid disease progression in IPF
patients [2, 10]. Fibroblastic foci are often strong sources
of TGF-β1 but expression is variable [26]. One unex-
pected finding in our study was that fibroblastic foci had
less CD248 staining than the areas of established fibro-
sis. One explanation for this could be our finding that
TGF-beta suppressed expression of CD248 in IPF de-
rived fibroblasts in contrast to its effects on normal lung
fiborblasts. (Fig. 3 and Additional file 1: Figure S4) A re-
cent article by Babu et al. [27] suggests that the TGF-β1-
mediated suppression of CD248 is present in normal
murine embryonic fibroblasts but not murine lymphoma
cell lines or in cancer-associated fibroblasts suggesting
perhaps that the local cellular environment influences
CD248 expression.
The fact, that TGF-β1 treatment leaves CD248 expres-
sion levels unchanged in normal lung fibroblasts but de-
creases the expression in IPF-derived cells (Fig. 3) allows
us to speculate about the changes in the regulation of
gene and protein expression occurring in IPF pathogen-
esis. Our results suggest that CD248 expression becomes
newly regulated by TGF-beta signalling in IPF. Interest-
ingly our experiments showed CD248 expression
changes only on the protein expression but not on the
mRNA levels (Fig. 3). This phenomenon is typical of
post-transcriptional protein regulation, so we
hypothesize that TGF-beta regulates CD248 protein
levels by influencing the post-transcriptional mecha-
nisms rather than the on the level of gene transcription.
However, the identification of the exact regulatory
mechanism is beyond the scope of this project. Higher
CD248 expression has been associated in tumour-
associated fibroblasts and pericytes while in normal
stroma CD248 is hardly detectable [28]. In pulmonary fi-
brosis we observed elevated CD248 expression. Similarly
Smith et al. described elevated CD248 expression in kid-
ney fibrosis [21]. Since it is known that CD248 binds to
ECM components, it is interesting to speculate that pro-
found changes can be observed in ECM modelling/re-
modelling in both fibrotic and malignant diseases and
how these changes might regulate CD248 expression
levels and ECM-derived cues for cellular functions, like
proliferation, adhesion and migration.
We found that CD248 is not expressed on pulmonary
epithelial cells during TGF-β1-induced epithelial-
mesenchymal transition, nor on a lung carcinoma cell
line (Fig. 5). This is in concordance with the findings of
Rouleau et al. [29] The authors describe high levels of
CD248 expression in the stromal components but not
on the malignant cells of carcinomas. Interestingly, the
malignant cells of sarcomas proved to be highly positive
for CD248 expression [19, 29]. These findings strongly
suggest that CD248 is a genuine mesenchymal marker
which is not induced by epithelial-mesenchymal transi-
tion in contrast to other mesenchymal proteins like
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Fig. 3 (See legend on next page.)
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S100A4 or vimentin [7, 30, 31]. Presently there is an on-
going debate on whether mesenchymal elements in fi-
brotic organs derive in large numbers from epithelial
cells [7]. Although CD248 is not a fibroblast-specific
marker [14, 24] these findings might highlight the use-
fulness of CD248 as a marker for separating
mesenchymal-like cells originating from epithelial cells
from genuine mesenchymal cells. This could aid
appropriate flow sorting protocols in studies looking at
epithelial mesenchymal interactions.
This research has its limitations. Firstly, immunohisto-
chemistry is not a truly quantitative technique as DAB
staining intensity shows no linear correlation with anti-
gen expression levels [22]. That is why we chose to
measure CD248 staining area instead of staining inten-
sity. By using the area of extent of CD248 staining
(See figure on previous page.)
Fig. 3 Measurement of expression levels of CD248 on human lung fibroblasts derived from normal (n = 6) and IPF lungs (n = 6). Panel a: Flow
cytometric histograms showing CD248 expression on human lung fibroblasts from normal (diagram on the left) and IPF lungs (diagram on the
right). Open histograms represent samples labelled with FITC-conjugated CD248 antibody, closed histograms represent FITC-conjugated isotype
control antibody. Two representative diagrams are shown of twelve independent samples. Panel b: CD248 expression changes in fibroblasts treated
with TGF-beta (n = 12). Bars represent median fluorescent intensities (average + SEM is shown of six independent samples). CD248 expression levels
were significantly higher (p < 0.001) in fibroblasts derived from IPF patients than in those from normal lungs. CD248 expression declined significantly
(p < 0.01) upon TGF-beta treatment in fibroblasts derived from IPF lungs but not in those from normal lungs. Panel c: CD248 mRNA expression levels
in fibroblasts treated with TGF-β1 derived from normal (n = 6) and IPF lungs (n = 6). Bars repesent CD248 Ct values compared to GAPDH. Note that
there are no significant differences between CD248 mRNA expression in different samples
Fig. 4 Panel a: CD248 knockdown with specific siRNA significantly reduced BrdU uptake in NHLFs (n = 3 different NHLF batches, total replicates
18, p < 0.001 with Student’s non-equal varienace t-test). Cells were incubated with 30 pmol of control or CD248-specific siRNA for 48 h. BrdU was
added according to the manufacturer’s recommendation (Calbiochem). BrdU incorporation was detected using an indirect ELISA method. Panel
b. CD248 expression in NHLF cells measured with flow cytometry (cells from n = 5 different donors). CD248-specific siRNA caused significant
(*p < 0.05, non-equal variance t-test) drop in the protein expression levels when compared to treatment with scrambled control siRNA. Median
Fluorescent intensity and Standard error of the mean (SEM) is plotted on the graph. Panel c. Intracellular Collagen 1a1 expression levels in NHLF
cells measured by flow cytometry (cells from n = 5 different donors). TGF-β1 treatment caused a significant elevation in collagen 1 synthesis
(*p < 0.01, non-equal variance t-test) but we measured no significant difference when cells were treated with CD248-specific siRNA. Median
Fluorescent intensity and Standard error of the mean (SEM) is plotted on the graph. Panel d. Intracellular alpha smooth muscle (aSMA)
expression levels in NHLF cells measured by flow cytometry (cells from n = 5 different donors). TGF-β1 treatment caused significant
increase in aSMA expression in NHLF cells regardless of siRNA treatment siRNA (p < 0.05, non-equal variance t-test). Median Fluorescent
intensity and Standard error of the mean (SEM) is plotted on the graph
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compared to the area stained by non-immune nuclear
stain haematoxylin we did show significant correlations
with disease severity and lung function. Further we dem-
onstrated that IPF derived fibroblasts do express greater
levels of CD248 than normal lung fibroblasts.
Secondly, whilst we demonstrated an inhibitory effect
of CD248 siRNA upon proliferation, this was a relatively
small effect but that may have been due to only 40-50 %
efficiency of CD248 knockdown. We were unable to test
the CD248 siRNA in IPF derived fibroblasts due to their
limited availability. Finally, CD248 siRNA did not affect
myofibroblast differentiation or collagen expression so
the exact role CD248 plays in fibrogenesis is still
unclear.
Conclusion
In conclusion, CD248 appears to be a specific marker of
mesenchymal cells that is elevated in the lungs of pa-
tients with IPF. It is noteworthy, that epithelial cells do
not express CD248 when undergoing EMT, in contrast
to other commonly used EMT biomarkers. CD248 ex-
pression correlated with markers of disease severity.
CD248 was functionally important in terms of prolifera-
tion of primary pulmonary fibroblasts but does not ap-
pear to alter myofibroblast differentiation. CD248 may
represent a novel therapeutic target in IPF to reduce
fibro-proliferation.
Ethical statement
All procedures in this study were performed in accord-
ance with approval from the local research ethics com-
mittees at the University of Birmingham and Newcastle
University. All patients included in this study gave writ-
ten informed consent for the use of their tissue and clin-
ical data for research purposes. Ethics committee
approval number 07/MRE08/42.
Consent for publication
Not applicable for this research.
Availability of data and materials
All relevant data and materials are published in the
manuscript and supplementary materials.
Additional file
Additional file 1: Supplementary material. (PDF 523 kb)
Abbreviations
a-SMA: alpha smooth muscle actin; ANOVA: analysis of variance; BrdU: 5-
bromo-2′-deoxyuridine; CD: cluster of differentiation; DAB: diaminobenzidine;
DMEM: Dulbecco’s modified Eagle’s Medium; DNA: deoxyribonucleic acid;
Dnase: deoxyribonuclease; ECM: extracellular matrix; ELISA: enzyme-linked
immunosorbent assay; EMT: epithelial-mesenchymal transition; FCS: fetal calf
serum; FEV1: forced expiratory volume in 1 s; FITC: fluorescein-isothiocianate;
FVC: forced vital capacity; HEPES: 4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid; IHC: immunohistochemistry; ILD: interstitial lung diseases; IPF: idiopathic
pulmonary fibrosis; KD: knock-down; MFI: median fluorescent intensitíy;
NHLF: Normal Human Lung Fibroblasts; NHS: National Health Service;
PCR: polimerase chain reaction; PDGF: platelet-derived growth factor;
qPCR: quantitative polimerase chain reaction; r2: r squared; RNA: ribonucleic
acid; siRNA: silencing ribonucleic acid; TEM-1: tumour endothelial marker-1;
TGF-β1: transforming growth factor beta 1; TLC: total lung capacity;
TLCO: transfer factor for carbon monoxide; VATS: video-assisted thoracoscopy.
Competing interests
All authors have declared no competing interests related to this publication.
Fig. 5 CD248 expression do not changes significantly in A549 (n = 3) or in primary type II alveolar epithelial cells (ATII, n = 6) upon TGF-β1
– induced EMT. Cells were treated with 10 ng/ml TGF-β1 for 72 h. mRNA expression levels of CD248, SLUG Vimentin (VIM) and GAPDH
were tested with reverse transcription quantitative PCR (RT-qPCR). On the graph, reverse dCt values are plotted; values were calculated as
described above. CD248 expression levels were very low and did not changed significantly upon growth factor treatments. In contrast,
expression levels of EMT markers SLUG and VIM were significantly elevated (*p < 0.05) in the TGF-β1-treated samples, indicating that
epithelial cells have undergone EMT
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